Compare Amylx Pharmaceuticals Inc (AMLX) vs Five Below Inc (FIVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Five Below Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Five Below Inc trades at $189.77 (market cap $10.47B). The key difference: Five Below Inc is far larger — about 5.3× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FIVE | |
|---|---|---|
Market Cap | $1.98B | $10.47B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $247.71 |
52-Week Low | $7.64 | $129.46 |
Enterprise Value | $1.70B | $11.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
FIVE trades at $189.39, up 2.8% today, with a bearish technical signal but strong fundamentals including a 36.81% gross margin and 21.13% ROE. Recent earnings beats and a 60% analyst buy rating support momentum, while expansion to 2,000 stores (GlobeNewsWire, July 9, 2026) highlights growth. The stock faces resistance near $191 with net cash flow positive at $152 million in 2025.
Outlook remains positive with a $252.09 consensus target, though risks include margin pressure from 2025's 6.54% net margin and bearish moving averages. Growth drivers are digital marketing and store openings, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
